Poolbeg Pharma’s results highlight expansion potential and promising new assets

The annual results released by biopharmaceutical company Poolbeg Pharma Plc (LON:POLB) highlighted the pipeline, personnel hires, and expansion potential of its signature asset POLB 001. Since that release, the pipeline has potentially expanded with an option agreement to acquire an orphan drug candidate for Behçet’s Disease, a condition that causes chronic inflammation or swelling in the body’s blood vessels and can lead to neurological complications like strokes. This candidate aligns with Poolbeg’s goal of developing and commercialising innovative medicines targeting diseases with high unmet medical needs. Poolbeg has 12 months for due diligence on this candidate, described by CEO Dr Jeremy Skillington as “a very interesting, very exciting asset with really good data.”

Poolbeg is renowned for its thorough research efforts, with a team experienced in launching similar businesses on the Nasdaq stock exchange. The company has appointed Shore Capital as its joint brokers, leveraging their expertise in biopharmaceutical listings on the U.S. stock exchange. The U.S. market is crucial for Poolbeg, not only for additional capital but also due to the presence of the FDA, which plays a key role in clinical trials and fast-tracking treatment commercialisation. The Behçet’s Disease candidate already has FDA Fast Track designation.

Additionally, POLB 001 has made progress in the U.S. with an Immunomodulator II patent grant, which strengthens the company’s intellectual property portfolio for partnering. According to Dr Skillington, POLB 001 shows immense promise in a $10 billion market, with data generation being equally important to protecting the company’s innovations.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

Poolbeg receives US patent for Immunomodulator development

Poolbeg Pharma plc, a clinical-stage biopharmaceutical company, has announced that the US Patent Office will grant its US Immunomodulator I patent application. The patent covers POLB 001, a selective p38 MAP kinase inhibitor, and other similar

Poolbeg Pharma awarded POLB 001 patent in United States

Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the US Patent Office has notified the Company of its official decision

AI in Pharmaceuticals

Artificial intelligence in the pharmaceutical industry has become central to modern drug discovery and development. Recognising both its potential and its risks, the FDA has initiated efforts to regulate AI’s role in the sector, balancing innovation

Poolbeg Pharma’s Oral GLP-1R agonist for metabolic disease

Poolbeg Pharma has developed a delivery system designed to enhance oral administration of GLP-1R agonists. This scalable, GRAS (Generally Recognised as Safe)-approved technology allows metabolic peptides to reach specific gut regions and enter systemic circulation, targeting

Poolbeg Pharma Scientist discusses Oral GLP-1 receptors

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

POLB 001: A promising treatment for severe influenza

Severe influenza is marked by an excessive immune response, which can cause considerable damage to the lungs and affect other organs. This uncontrolled reaction often leads to hospitalisation due to the impact it has on the

Advancements shaping the future of drug discovery

The landscape of drug discovery has long been known for its complexity and the substantial time and financial resources required to bring a single drug to the market. Traditional methods, while forming the backbone of the

Poolbeg Pharma patent portfolio significantly strengthened & expanded

Poolbeg Pharma plc (LON: POLB), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced its unaudited interim results for the six months to 30 June 2024.

UCD leads in research collaboration and Poolbeg Pharma partnership

University College Dublin (UCD) has been recognised for leading the way in research collaboration with industry in Ireland, according to Knowledge Transfer Ireland’s latest Annual Knowledge Transfer Survey (AKTS) for 2023. UCD, through its knowledge transfer